Key Highlights
- Zimmer Biomet Expands Robotics Portfolio with FDA-Cleared Semi- and Fully Autonomous Systems from Monogram
The $177 million deal includes upfront cash and milestone payments through 2030, reflecting strong confidence in disruptive AI-guided robotic surgery technologies. - Integration with Zimmer’s ROSA Robotics Platform Expected to Drive Revenue Growth Starting 2027
Monogram’s CT-based knee arthroplasty technology will be commercialized alongside Zimmer implants, with plans for robust expansion into autonomous surgical applications beyond knees. - Zimmer Positions Itself as a Leader in Surgical Robotics by Offering the Most Comprehensive and Flexible Technology Suite
The acquisition enhances offerings across imageless, CT-based, mixed reality, AI navigation, and autonomous robotic surgery with broad applicability to orthopedic procedures.
Strategic Acquisition Enhances Zimmer Biomet’s Robotics Leadership
Zimmer Biomet’s acquisition of Monogram Technologies, announced in July 2025, adds innovative semi-autonomous and fully autonomous robotic capabilities to its surgical portfolio. This acquisition aligns with Zimmer’s commitment to advance the future of orthopedic surgery through AI and automation.
Monogram’s Industry-Leading AI-Navigated Knee Arthroplasty Technology
Monogram’s mBôS robotic system, cleared by the FDA in early 2025, uses AI-driven, CT-based navigation for total knee arthroplasty. Full commercialization with Zimmer implant systems is anticipated in early 2027. The company is developing fully autonomous hands-free robotic surgery that aims to improve safety, efficiency, and outcomes by late 2027 or early 2028.
Complementary Integration with Zimmer’s ROSA Platform and Expanding Robotics Ecosystem
ROSA, with nearly 2,000 global installations, currently supports imageless and non-CT robotic surgery. The Monogram acquisition will enable Zimmer to offer options tailored to surgeon preferences, spanning manual, semi-autonomous, and fully autonomous solutions with plans for additional orthopedic applications.
Financial Impact and Market Outlook
The transaction, valued at approximately $177 million in equity with contingent payments up to $12.37 per share tied to milestones, is projected to be neutral to adjusted earnings per share through 2027, becoming accretive thereafter. Revenue contributions are expected to begin in 2027, supporting Zimmer’s position in the rapidly growing $16 billion global orthopedic robotics market.
For more details, visit Zimmer Biomet’s announcement
By
